Swiss healthcare giant Roche is advancing prasinezumab, a potential first-in-class anti-alpha-synuclein antibody for early Parkinson’s disease, into Phase III trials. This decision follows encouraging data from the Phase IIb PADOVA study and its long-term follow-up, suggesting the drug offers clinical benefits.
Parkinson’s disease
The different patterns of illness development that the subtypes exhibited allowed the investigators to identify them.
On World Parkinson’s Day, a new hypothesis study combines the body-first and brain-first theories with environmental toxicants that may be consumed or breathed as potential origins of the condition.
Researchers have discovered that phosphorylated α-synuclein, a protein linked to several neurodegenerative illnesses, including Parkinson’s disease and Lewy body dementia, is also engaged in the regular processes of neuronal communication in a healthy brain. The National Institute of Neurological Disorders and Stroke (NINDS), a division of the National Institutes of Health, provided […]
Bayer confirms the positive results of their Parkinson’s stem cell therapy initial trial developed by their subsidiary BlueRock Therapeutics. The trial was conducted on 12 patients which shows signs of reducing the Parkinson’s disease symptoms. Earlier, Bayer announced the success of the trial but the details were withheld. “Bayer AG […]
